title: The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation.
abstract: Nephrogenic systemic fibrosis (NSF) is a debilitating disease in patients with severely diminished kidney function. Currently, no standard treatment exists but improvement has been reported after restoration of kidney function. We retrospectively studied 17 NSF patients with and without successful kidney transplantation (KTx) to evaluate the effects of KTx on NSF. Nine of the 11 KTx developed NSF pretransplant whereas two developed NSF immediately after KTx with delayed graft function. Two of the six dialysis patients had previous failed kidney transplants. Age and sex were well matched. All but one patient was dialysis dependent at the time of NSF. Median follow-up was 35 months for KTx patients and 9 months for dialysis patients. Kidney transplants achieved adequate renal function with median serum creatinine of 1.4 (0.9-2.8) mg/dL and a glomerular filtration rate of 42 (19-60) mL/min/1.73 m(2). NSF improved in 54.6% of the transplanted patients and 50% of the nontransplanted patients (p = 0.86). Two KTx patients had complete resolution of their symptoms whereas four had partial improvement. Improvement in the dialysis patients was all partial. Successful KTx did not insure improvement in NSF and in fact appeared to have no significant benefit over dialysis.
authors.affiliation: Division of Nephrology and Hypertension, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA. leung.nelson@mayo.edu
authors.forename: N
authors.initials: N
authors.lastname: Leung
authors.forename: A
authors.initials: A
authors.lastname: Shaikh
authors.forename: F G
authors.initials: FG
authors.lastname: Cosio
authors.forename: M D
authors.initials: MD
authors.lastname: Griffin
authors.forename: S C
authors.initials: SC
authors.lastname: Textor
authors.forename: J M
authors.initials: JM
authors.lastname: Gloor
authors.forename: T R
authors.initials: TR
authors.lastname: Schwab
authors.forename: T S
authors.initials: TS
authors.lastname: Larson
authors.forename: P G
authors.initials: PG
authors.lastname: Dean
authors.forename: M
authors.initials: M
authors.lastname: Prieto
authors.forename: S L
authors.initials: SL
authors.lastname: Nyberg
authors.forename: M D
authors.initials: MD
authors.lastname: Stegall
authors.forename: C U
authors.initials: CU
authors.lastname: Lee
authors.forename: M R
authors.initials: MR
authors.lastname: Pittelkow
mesh_terms: D000328:Adult; D000368:Aged; D003404:Creatinine / Q000097:blood; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D054989:Nephrogenic Fibrosing Dermopathy / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D003404:Creatinine